读书报告

报告人:刘亦斌 导师:金群华教授 2019-05-15

Journal of Pharmacological Sciences 133 (2017) 18-24



Contents lists available at ScienceDirect

Journal of Pharmacological Sciences

journal homepage: www.elsevier.com/locate/jphs



Full paper

Celecoxib inhibits osteoblast maturation by suppressing the expression of Wnt target genes



Akihiro Nagano ^{a, b, 1}, Masaki Arioka ^{a, 1}, Fumi Takahashi-Yanaga ^{a, c, *}, Etsuko Matsuzaki ^{b, d}, Toshiyuki Sasaguri ^a

^a Department of Clinical Pharmacology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan

^b Periodontology Section, Division of Oral Rehabilitation, Faculty of Dental Sciences, Kyushu University, Fukuoka, Japan

^c Global Medical Science Education Unit, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan

^d Section of Operative Dentistry and Endodontology, Department of Odontology, Fukuoka Dental College, Fukuoka, Japan

Celecoxib inhibits osteoblast maturation by suppressing the expression of Wnt target genes

Abstract.

- Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to impair bone healing. We previously reported that in colon cancer cells, celecoxib, a COX-2-selective NSAID, inhibited the canonical Wnt/b-catenin signaling pathway.
- Subsequently, we analyzed the effect of celecoxib on two osteoblast differentiation markers; runt-related transcription factor 2 (RUNX2) and alkaline phosphatase (ALP), both of which are the products of the canonical Wnt pathway target genes. Celecoxib inhibited the expression of both RUNX2 and ALP by suppressing their promoter activity. Consistent with these observations, celecoxib also strongly inhibited osteoblast-mediated mineralization.
- These results suggest that celecoxib inhibits osteoblast maturation by suppressing Wnt target genes, and this could be the mechanism that NSAIDs inhibit bone formation and fracture healing.

Introduction

- We and others showed that celecoxib inhibits cancer cell growth by inhibiting the Wnt/b-catenin signaling (canonical Wnt) pathway.
- Among them, the canonical Wnt pathway is a major osteogenic signaling cascade in osteoblast to induce differentiation and maturation, which up-regulates (RUNX2) runt-related transcription factor 2, an essential transcription factor for osteoblast differentiation.
- Here, we show that celecoxib prevents osteoblast maturation by reduction of TCF7L2 and its downstream gene products, RUNX2 and alkaline phosphatase (ALP)

RESULTS

50

1、 Celecoxib inhibited the canonical Wnt pathway in MC3T3-E1



1、 Celecoxib inhibited the canonical Wnt pathway in MC3T3-E1



2、 Celecoxib inhibited RUNX2 expression

2、 Celecoxib inhibited RUNX2 expression

3、Celecoxib suppressed ALP expression by suppression of the promoter activity

3、Celecoxib suppressed ALP expression by suppression of the promoter activity

4、 TCF7L2 depletion suppressed RUNX2 and ALP expressions

5、 Celecoxib suppressed osteoblast-mediated mineralization

Discussion

1. In this study, we found that celecoxib inhibited the canonical Wnt pathway by suppressing TCF7L2 expression and thereby reduced amounts of RUNX2 and ALP, via inhibition of their promoters' activity. Further, we found that celecoxib strongly suppressed osteoblast-mediated mineralization. that this could be the one mechanism by which celecoxib inhibits bone formation and fracture healing.

2、 NSAIDs, including COX-2 specific inhibitor, are known to prevent bone formation and fracture healing in vivo.

3. Therefore, celecoxib might suppress the Wnt/b-catenin signaling pathway via two different mechanisms, the degradation of TCF7L2 and the inhibition of PGE2 production, thereby inhibiting bone formation and fracture healing.

• 2019-05-15